AKRO vs LLY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LLY Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Eli Lilly & Co. (LLY) driven by superior Valuation, Growth & Margin, Options & Structure while AKRO counters with relative strength in Momentum & Technical. Fundamentally, AKRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LLY at 26.5x Forward P/E and 51.2% operating margin (+38.6% YoY). In options structure, AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro) against LLY sits in CONSOLIDATION (23rd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AKRO | LLY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.5B | $1.20T | Larger Scale | LLY |
| Trailing P/E Ratio Valuation | N/M | 44.9x | Lower Multiple | LLY |
| Forward P/E Ratio Valuation | N/M | 26.5x | Lower Multiple | LLY |
| Revenue Growth (YoY) Growth | +0.0% | +38.6% | Higher Growth | LLY |
| Operating Margin (TTM) Profitability | 0.0% | 51.2% | Higher Margin | LLY |
| Net Profit Margin Profitability | 0.0% | 31.9% | Higher Margin | LLY |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 86.0% | Higher ROE | LLY |
| 52-Week Range Position Momentum | 90% ($21โ$58) | 80% ($851โ$1,475) | Stronger Trend | AKRO |
| Beta / 30D Volatility Risk Regime | 0.90ฮฒ ยท 2% Vol | 0.32ฮฒ ยท 36% Vol | Lower Realized Risk | AKRO |
| Unified Institutional Score Composite Signal | 60.0 / 100 (BUY) | 41.4 / 100 (SELL) | Higher Composite | AKRO |